HLA sequencing data

This study included 299 SARS-CoV-2 infected patients. During April-May 2020, blood and nasopharyngeal swab samples from patients were collected in six hospitals of the Health Ministry of the Republic of Armenia: National Center for Infection Diseases, Surb Grigor Lusavorich, Surb Astvatsamayr and Artashat Medical Centres, Maralik and Akhuryan Mother and Child Health Centers. The diagnosis was performed on nasopharyngeal specimens by detection of SARS-CoV-2 RNA, using the following kits: SARS-CoV-2/SARS-CoV Multiplex REAL-TIME PCR Detection Kit (LLC “NPF DNA-Technology”, Cat. No. R3-P436-23/9EU), LiliF™ COVID-19 Real-time RT-PCR Kit (iNtRON Biotechnology, Cat. No. IPH21505.50) and Real-time-fluorescent-RT-PCR (BGI, Cat. No. HW5105). Patients were classified into three groups according to their disease symptoms. The severe disease group (n=122) comprised patients with severe respiratory problems, who required critical care at ICU and the use of oxygen supplementation and/or mechanical ventilation. In the second group, namely mild (in figures) symptomatic group (n=102), were included patients hospitalized during the same period with various mild and moderate COVID-19 symptoms, such as fever, loss of taste, body aches, fatigue, etc., but not requiring ICU admission. The asymptomatic group (n=75) consisted of hospital staff at the COVID-19 treating centers who tested positive for the virus but had no symptoms. Blood samples (3 ml, EDTA) were sent out to HistoGenetics LLC laboratory (Ossining, NY) for HLA sequencing of HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQA1, HLA-DQB1, HLA-DPA1, and HLA-DPB1 loci (25). Next-generation sequencing was performed using Illumina MiSeq and PacBio platforms.